Chang Ho Ahn

USPTO Granted Patents = 11 (Patent Applications = 2)

CIPO Patents = 3 (Patent Applications = 1)

EPO Patents = 1 (Patent Applications = 3)

Average Co-Inventor Count = 2.7

ph-index = 4

Forward Citations = 51(Granted Patents)

Location History:

Los Angeles, CA (US) (2003)
Rockville, MD (US) (2013 - 2014)
Potomac, MD (US) (2006 - 2019)

Company Filing History:

7 out of 19

Rexahn Pharmaceuticals, Inc.

Korea Research Institute of Chemical Technology

patents

4. 1 out of 827

The Ohio State University

patents

5. 1 out of 1,926

University System of Maryland

patents

6. 1 out of 832,680

Other

patents

where one patent can have more than one assignee

Years Active: 2003-2019

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10307490 - Lipid nanoparticle compositions for antisense oligonucleotides delivery (2019-06-04),

2. 9434610 - HPMA—docetaxel conjugates and uses therefore (2016-09-06),

3. 8846110 - Polymeric systems for the delivery of anticancer drugs (2014-09-30),

4. 8598173 - 1-[(6,7-substituted alkoxyquinoxalinyl)aminocarbonyl]-4-(hetero)arylpiperazine derivatives for treating tumors (2013-12-03),

5. 8404698 - Quinazoline derivatives and therapeutic use thereof (2013-03-26),

6. 8314123 - 5, 6, or 7-substituted -3-(hetero) arylisoquinolinamine derivatives and therapeutic use thereof (2012-11-20),

7. 8034829 - 5, 6, or 7-substituted-3-(hetero)arylisoquinolinamine derivatives and therapeutic use thereof (2011-10-11),

8. 7405214 - Nucleoside derivatives and therapeutic use thereof (2008-07-29),

9. 7388014 - Quinazoline derivatives and therapeutic use thereof (2008-06-17),

10. 7122527 - Use of antisense oligonucleotides to inhibit the expression of human Akt-1 (2006-10-17),

11. 6510856 - Apparatus and method for hair extension (2003-01-28),

Title: The Inventor Chang Ho Ahn: Leading Innovations in Nanoparticles for Cancer Treatment

Introduction:

Chang Ho Ahn is a prolific inventor based in Potomac, MD, with an impressive portfolio of 10 patents. His groundbreaking work focuses on lipid nanoparticle compositions for the delivery of antisense oligonucleotides, with a particular emphasis on targeting agents for therapeutic purposes.

Latest Patents:

One of Ahn's latest patents involves lipid nanoparticle compositions for delivering antisense oligonucleotides. These compositions include a macromolecule conjugated to a polymer and a targeting agent, with applications in treating cancers by modulating the expression of key genes like Akt-1 and HIF-1.

Another notable patent by Ahn is the development of HPMA–docetaxel conjugates, showcasing water-soluble compositions of gemcitabine and docetaxel for effective cancer treatment by utilizing a water-soluble polymer such as N-2-hydroxypropyl methacrylamide (HPMA).

Career Highlights:

Ahn has left a mark in notable pharmaceutical companies like Rexahn Pharmaceuticals, Inc. and Rexahn Corporation, where his innovative research and patent work have significantly contributed to advancements in cancer treatment. His dedication to developing novel therapeutic approaches has garnered recognition in the field.

Collaborations:

Ahn has collaborated with esteemed professionals in the field, including coworkers such as Young Bok Lee and Deog Joong Kim. Together, they have synergized their expertise to push the boundaries of nanoparticle technology for targeted drug delivery and precision medicine applications.

Conclusion:

In conclusion, Chang Ho Ahn stands as a pioneering figure in the realm of nanoparticle-based drug delivery systems for cancer treatment. His patent portfolio reflects a commitment to innovation and a relentless pursuit of solutions that have the potential to revolutionize the way we approach therapeutic interventions in oncology.

This text is generated by artificial intelligence and may not be accurate.